



## Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

March 29, 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Mar. 29, 2021-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time.

A live audio webcast of the company's presentation will be available by visiting Castle Biosciences' website at <https://ir.castlebiosciences.com/news-events/events-presentations>. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

### About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx<sup>®</sup>-Melanoma, DecisionDx<sup>®</sup>-CMSeq), cutaneous squamous cell carcinoma (DecisionDx<sup>®</sup>-SCC), suspicious pigmented lesions (DecisionDx<sup>®</sup> DiffDx<sup>™</sup>-Melanoma) and uveal melanoma (DecisionDx<sup>®</sup>-UM, DecisionDx<sup>®</sup>-PRAME and DecisionDx<sup>®</sup>-UMSeq). For more information about Castle's gene expression profile tests, visit [www.CastleTestInfo.com](http://www.CastleTestInfo.com). Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit [www.CastleBiosciences.com](http://www.CastleBiosciences.com).

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210329005745/en/): <https://www.businesswire.com/news/home/20210329005745/en/>

Investor and Media Contact:

Camilla Zuckero

832-835-5158

[czuckero@castlebiosciences.com](mailto:czuckero@castlebiosciences.com)

Source: Castle Biosciences, Inc.